The Effect of the 10-Valent Pneumococcal NontypeableHaemophilus influenzaeProtein D Conjugate Vaccine onH. influenzaein Healthy Carriers and Middle Ear Infections in Iceland
ABSTRACTVaccinations with the 10-valent pneumococcal conjugated vaccine (PHiD-CV) started in Iceland in 2011. Protein D (PD) fromH. influenzae, which is coded for by thehpdgene, is used as a conjugate in the vaccine and may provide protection against PD-positiveH. influenzae. We aimed to evaluate the effect of PHiD-CV vaccination onH. influenzaein children, both in carriage and in acute otitis media (AOM).H. influenzaewas isolated from nasopharyngeal swabs collected from healthy children attending 15 day care centers in 2009 and from 2012 to 2017 and from middle ear (ME) samples from children with AOM collected from 2012 to 2017. All isolates were identified using PCR for thehpdandfucKgenes. Of the 3,600 samples collected from healthy children, 2,465 were culture positive forH. influenzae(68.5% carriage rate); of these, 151 (6.1%) containedhpd-negative isolates. Of the 2,847 ME samples collected, 889 (31.2%) were culture positive forH. influenzae; of these, 71 (8.0%) werehpdnegative. Despite the same practice throughout the study, the annual number of ME samples reduced from 660 in 2012 to 330 in 2017. The proportions ofhpd-negative isolates in unvaccinated versus vaccinated children were 5.6% and 7.0%, respectively, in healthy carriers, and 5.4% and 7.8%, respectively, in ME samples. The proportion ofhpd-negative isolates increased with time in ME samples but not in healthy carriers. The number of ME samples from children with AOM decreased. The PHiD-CV had no effect on the proportion of thehpdgene inH. influenzaefrom carriage, but there was an increase inhpd-negativeH. influenzaein otitis media. The proportions ofhpd-negative isolates remained similar in vaccinated and unvaccinated children.